Image Source: Good Housekeeping
The FDA chlorthalidone dissolution testing recall has been elevated to a Class II recall, putting renewed attention on a blood pressure medication used by patients across the United States. The September 3, 2026, recall involves more than 13,000 bottles of chlorthalidone 25 mg tablets manufactured by Inventia Healthcare Limited.
The recall affects one specific lot of the prescription medicine after it failed dissolution specifications. That testing issue could mean the active ingredient does not dissolve properly in the body, potentially reducing how much medication is absorbed and making the treatment less effective than intended.
Critical Details in the Chlorthalidone Recall
Chlorthalidone is a diuretic, often called a “water pill.” It helps the kidneys remove excess water and salt from the body. Doctors prescribe it to help lower high blood pressure and reduce fluid retention.
Controlling blood pressure is important because untreated or poorly controlled hypertension can increase the risk of heart attack, heart disease, heart failure, stroke, kidney damage and vision-related complications. For that reason, patients should take the recall seriously without making sudden medication changes on their own.
The FDA classified the September recall as Class II on September 17. According to the agency’s recall classification system, a Class II recall involves a product that could cause temporary or medically reversible health problems. However, the probability of serious harm is considered remote.
What Failed Dissolution Testing Means
Dissolution testing measures how well a drug’s active ingredient separates from its tablet form so it can be absorbed by the body. If a tablet dissolves too slowly, too quickly or incompletely, the patient may not receive the expected amount of medicine.
In this case, the FDA and Inventia Healthcare identified failed dissolution specifications as the reason for the recall. No additional details about the testing failure were provided in the available recall information. The issue does not necessarily mean every tablet is defective, but only the identified lot should be treated as affected.
How to Identify the Recalled Medication
Patients and caregivers should check the prescription bottle or contact their pharmacist to confirm whether their medication matches all of the following details:
- Product: Chlorthalidone tablets, USP, 25 mg
- Package: 100 tablets per bottle, prescription only
- Manufacturer: Inventia Healthcare Limited
- NDC: 64980-599-01
- Batch number: RISA24002
- Expiration date: 04/2027
If even one detail is unclear, do not guess. A pharmacist can help verify the product, lot number and expiration date. Prescription labels may not always display every piece of recall information, so professional confirmation is especially useful.
What Patients Should Do Next
Anyone who believes they have the recalled chlorthalidone should contact their healthcare provider or pharmacist promptly. Do not stop taking chlorthalidone or switch to another blood pressure medication without medical guidance. Suddenly discontinuing treatment could allow blood pressure to rise and may create additional health risks.
A healthcare professional can explain whether the medication should be replaced, whether a different lot is available and how to continue managing blood pressure safely. Patients who feel unwell should report their symptoms immediately and mention the recalled medicine, the batch number and when they took it.
This is the second Class II chlorthalidone recall involving Inventia Healthcare in 2026. The company previously recalled certain lots in June. The September action is separate and specifically concerns batch RISA24002.
Why This Medication Alert Matters
Medication recalls can be stressful, particularly for people who rely on daily treatment for chronic conditions. The most important step is to verify the product rather than panic or stop therapy abruptly. Patients should keep taking medicines exactly as prescribed until a clinician or pharmacist provides individualized instructions.
Consumers should also monitor official FDA announcements, communicate with their healthcare team and keep an updated list of all prescription medications. That information can help providers quickly assess possible replacements or treatment adjustments during a recall.
Frequently Asked Questions
What is the FDA chlorthalidone dissolution testing recall?
It is a recall of one lot of chlorthalidone 25 mg tablets made by Inventia Healthcare Limited. The lot was recalled after failing dissolution specifications, which could affect how well the drug is absorbed.
How many bottles are included in the recall?
More than 13,000 bottles are involved in the September 2026 recall.
Is the recalled chlorthalidone dangerous?
The FDA classified the recall as Class II. That means temporary or medically reversible health effects are possible, while the risk of serious harm is considered remote. Patients should still contact a healthcare professional for advice.
Should I stop taking chlorthalidone?
No. Do not stop or change your medication without speaking with your healthcare provider or pharmacist. They can confirm whether your bottle is affected and recommend a safe next step.
